168 related articles for article (PubMed ID: 30456527)
1. The potential role of Ets-1 and miR-326 in CD19
Jin L; Fang X; Dai C; Xiang N; Tao J; Sun X; Azmi F; Cao Q; Li X; Wang Y; Li X
Clin Rheumatol; 2019 Apr; 38(4):1031-1038. PubMed ID: 30456527
[TBL] [Abstract][Full Text] [Related]
2. [Role of transcription factor ETS-1 and B cell in the pathogenesis of systemic lupus erythematosus].
Ren QJ; Li XP; Tao JH; Yu N; Li XM; Wang GS; Zhang H; Fang X
Zhonghua Yi Xue Za Zhi; 2013 Aug; 93(31):2483-6. PubMed ID: 24300270
[TBL] [Abstract][Full Text] [Related]
3. Negative Correlation Between miR-326 and Ets-1 in Regulatory T Cells from new-Onset SLE Patients.
Sun XG; Tao JH; Xiang N; Li XM; Wang GS; Fang X; Dai C; Zhang M; Chen Z; Li XP
Inflammation; 2016 Apr; 39(2):822-9. PubMed ID: 26861134
[TBL] [Abstract][Full Text] [Related]
4. Up-regulation of transcription factor Blimp1 in systemic lupus erythematosus.
Luo J; Niu X; Liu H; Zhang M; Chen M; Deng S
Mol Immunol; 2013 Dec; 56(4):574-82. PubMed ID: 23911415
[TBL] [Abstract][Full Text] [Related]
5. A functional variant in microRNA-146a promoter modulates its expression and confers disease risk for systemic lupus erythematosus.
Luo X; Yang W; Ye DQ; Cui H; Zhang Y; Hirankarn N; Qian X; Tang Y; Lau YL; de Vries N; Tak PP; Tsao BP; Shen N
PLoS Genet; 2011 Jun; 7(6):e1002128. PubMed ID: 21738483
[TBL] [Abstract][Full Text] [Related]
6. CD19/22 balance relates to improvement of disease activity in systemic lupus erythematosus.
Suzuki J; Nakano S; Nakairi Y; Mitsuo A; Amano H; Morimoto S; Tokano Y; Takasaki Y
Mod Rheumatol; 2006; 16(4):235-8. PubMed ID: 16906374
[TBL] [Abstract][Full Text] [Related]
7. Reduction of CD19 autoimmunity marker on B cells of paediatric SLE patients through repressing PU.1/TNF-α/BAFF axis pathway by miR-155.
Aboelenein HR; Hamza MT; Marzouk H; Youness RA; Rahmoon M; Salah S; Abdelaziz AI
Growth Factors; 2017 Jun; 35(2-3):49-60. PubMed ID: 28683581
[TBL] [Abstract][Full Text] [Related]
8. Differential expression pattern of microRNAs in CD4+ and CD19+ cells from asymptomatic patients with systemic lupus erythematosus.
Martínez-Ramos R; García-Lozano JR; Lucena JM; Castillo-Palma MJ; García-Hernández F; Rodríguez MC; Núñez-Roldán A; González-Escribano MF
Lupus; 2014 Apr; 23(4):353-9. PubMed ID: 24509687
[TBL] [Abstract][Full Text] [Related]
9. Activation of TLR7 increases CCND3 expression via the downregulation of miR-15b in B cells of systemic lupus erythematosus.
Ren D; Liu F; Dong G; You M; Ji J; Huang Y; Hou Y; Fan H
Cell Mol Immunol; 2016 Nov; 13(6):764-775. PubMed ID: 26144250
[TBL] [Abstract][Full Text] [Related]
10. Peripheral CD24hi CD27+ CD19+ B cells subset as a potential biomarker in naïve systemic lupus erythematosus.
Jin L; Weiqian C; Lihuan Y
Int J Rheum Dis; 2013 Dec; 16(6):698-708. PubMed ID: 24286662
[TBL] [Abstract][Full Text] [Related]
11. Ets-1: a new player in the pathogenesis of systemic lupus erythematosus?
Pan HF; Leng RX; Tao JH; Li XP; Ye DQ
Lupus; 2011 Mar; 20(3):227-30. PubMed ID: 21362749
[TBL] [Abstract][Full Text] [Related]
12. TLR9-induced miR-155 and Ets-1 decrease expression of CD1d on B cells in SLE.
Liu F; Fan H; Ren D; Dong G; Hu E; Ji J; Hou Y
Eur J Immunol; 2015 Jul; 45(7):1934-45. PubMed ID: 25929465
[TBL] [Abstract][Full Text] [Related]
13. Increased Syk phosphorylation leads to overexpression of TRAF6 in peripheral B cells of patients with systemic lupus erythematosus.
Iwata S; Yamaoka K; Niiro H; Jabbarzadeh-Tabrizi S; Wang SP; Kondo M; Yoshikawa M; Akashi K; Tanaka Y
Lupus; 2015 Jun; 24(7):695-704. PubMed ID: 25432781
[TBL] [Abstract][Full Text] [Related]
14. CD19
Xiong H; Tang Z; Xu Y; Shi Z; Guo Z; Liu X; Tan G; Ai X; Guo Q
Adv Rheumatol; 2022 Dec; 62(1):48. PubMed ID: 36494762
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-21 is increased in active systemic lupus erythematosus patients and contributes to the generation of plasma B cells.
Nakou M; Papadimitraki ED; Fanouriakis A; Bertsias GK; Choulaki C; Goulidaki N; Sidiropoulos P; Boumpas DT
Clin Exp Rheumatol; 2013; 31(2):172-9. PubMed ID: 23137515
[TBL] [Abstract][Full Text] [Related]
16. The role and clinical significance of programmed cell death- ligand 1 expressed on CD19
Jia XY; Zhu QQ; Wang YY; Lu Y; Li ZJ; Li BQ; Tang J; Wang HT; Song CW; Xie CH; Chen LJ
Clin Immunol; 2019 Jan; 198():89-99. PubMed ID: 30502542
[TBL] [Abstract][Full Text] [Related]
17. Elevated CD19
Ju B; Wang J; Mo L; Huang J; Hao Z; Lv X; Pu D; He L
Int Immunopharmacol; 2022 Jan; 102():108403. PubMed ID: 34857478
[TBL] [Abstract][Full Text] [Related]
18. CD81 and CD19 as Marker of Activity in Systemic Lupus Erythematosus Disease.
Abu-Zahab Z; Gad NM; Sabry S; Nassib SA
Egypt J Immunol; 2017 Jun; 24(2):141-149. PubMed ID: 29528587
[TBL] [Abstract][Full Text] [Related]
19. Enhanced Tyrosine Phosphatase Activity Underlies Dysregulated B Cell Receptor Signaling and Promotes Survival of Human Lupus B Cells.
Fleischer SJ; Daridon C; Fleischer V; Lipsky PE; Dörner T
Arthritis Rheumatol; 2016 May; 68(5):1210-21. PubMed ID: 26713408
[TBL] [Abstract][Full Text] [Related]
20. High expression of VTRNA2-1 in systemic lupus erythematosus patients' B lymphocytes and its significance.
Wan M; Qiu X; Lu Q
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2020 Feb; 45(2):123-127. PubMed ID: 32386035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
